Prevalence of sensitization to grass pollen purified allergens in patients allergic to grass pollen Source: Eur Respir J 2002; 20: Suppl. 38, 507s Year: 2002
A single recombinant hybrid molecule consisting of the major Timothy grass pollen allergens allowed in vivo and in vitro diagnosis of grass pollen allergy Source: Eur Respir J 2006; 28: Suppl. 50, 676s Year: 2006
Sublingual specific immunotherapy in the treatment of hay fever caused by tree pollen in children Source: Annual Congress 2010 - Clinical aspects of asthma and allergic respiratory diseases Year: 2010
Hypoallergenic high dose scit as add-on therapy in children with allergic asthma caused by house dust mites Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009
Bronchial challenge with flour: early response is dependent on the dose of activated allergen inhaled Source: Eur Respir J 2002; 20: 409-416 Year: 2002
Evaluation of specific IgE to recombinant pollen allergens in asthmatic patients with specific IgE to phleum pratense Source: Eur Respir J 2001; 18: Suppl. 33, 434s Year: 2001
IgE specific for recombinant grass pollen allergens in allergic respiratory disease Source: Eur Respir J 2005; 26: Suppl. 49, 380s Year: 2005
Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007
Effects of 3-yr immunotherapy with standardised extracts of house dust mite in allergic asthmatic subjects receiving appropriate drug treatment Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002
Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021
Relationship between ragweed pollen counts and delivery of anti allergic medication Source: Eur Respir J 2002; 20: Suppl. 38, 121s Year: 2002
Efficacy and safety of 300IR 5-grass pollen sublingual tablet in allergic patients with and without asthma Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012
Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 438s Year: 2006
Safety of 5-grass pollen extract sublingual tablet in patients with grass pollen-induced allergic rhinoconjunctivitis and concomitant intermittent asthma: A pooled analysis Source: Annual Congress 2013 –Treatment of asthma Year: 2013
Efficacy of specific allergy vaccination in house dust mite asthma Source: Eur Respir J 2005; 26: Suppl. 49, 465s Year: 2005
House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020
Safety of subcutaneous immunotherapy with standardized extracts of house dust mite in allergic asthmatic subjects Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002
Phospho-STAT-6 levels in nasal scrapings of asthmatic patients increases following nasal challenge with grass but not house dust mite allergen Source: Annual Congress 2009 - Novel mechanisms in the pathogenesis of asthma Year: 2009
Estimation of prevalence of grass pollen sensitization among patients with seasonal allergic rhinitis in Armenia Source: International Congress 2018 – Asthma, rhinitis and COPD: cells, mediators, biomarkers and genetics Year: 2018
High doses of sublingual tablets of house dust mite allergen extracts: Lung function assessment in a phase I study in adults with mite-associated allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015